Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Molecular basis for prostate cancer racial disparities.

Singh SK, Lillard JW Jr, Singh R.

Front Biosci (Landmark Ed). 2017 Jan 1;22:428-450. Review.

2.

Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.

Han JH, Lee YS, Kim HJ, Lee SY, Myung SC.

Asian J Androl. 2015 Mar-Apr;17(2):285-91. doi: 10.4103/1008-682X.133320.

3.

Genetic variation: effect on prostate cancer.

Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R.

Biochim Biophys Acta. 2014 Dec;1846(2):446-56. doi: 10.1016/j.bbcan.2014.08.007. Epub 2014 Sep 6. Review.

4.

Establishment and characterization of a highly tumorigenic African American prostate cancer cell line, E006AA-hT.

Koochekpour S, Willard SS, Shourideh M, Ali S, Liu C, Azabdaftari G, Saleem M, Attwood K.

Int J Biol Sci. 2014 Jul 26;10(8):834-45. doi: 10.7150/ijbs.9406. eCollection 2014.

5.

Ethnic background and genetic variation in the evaluation of cancer risk: a systematic review.

Jing L, Su L, Ring BZ.

PLoS One. 2014 Jun 5;9(6):e97522. doi: 10.1371/journal.pone.0097522. eCollection 2014. Review.

6.

Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Li J, Mercer E, Gou X, Lu YJ.

Am J Cancer Res. 2013 Apr 3;3(2):127-51. Print 2013.

7.

CYP17 T27C polymorphism and prostate cancer risk: a meta-analysis based on 31 studies.

Wei B, Zhang Y, Xi B, Chang J, Bai J, Su J.

J Biomed Res. 2010 May;24(3):233-41. doi: 10.1016/S1674-8301(10)60033-4.

8.

Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.

Taioli E, Sears V, Watson A, Flores-Obando RE, Jackson MD, Ukoli FA, de Syllos Cólus IM, Fernandez P, McFarlane-Anderson N, Ostrander EA, Rodrigues IS, Stanford JL, Taylor JA, Tulloch-Reid M, Ragin CC.

Prostate. 2013 May;73(6):668-76. doi: 10.1002/pros.22612. Epub 2012 Nov 5.

9.

CYP17 polymorphisms and prostate cancer outcomes.

Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, Ostrander EA, Stanford JL.

Prostate. 2010 Jul 1;70(10):1094-101. doi: 10.1002/pros.21143.

10.

Review of studies on metabolic genes and cancer in populations of African descent.

Ragin CC, Langevin S, Rubin S, Taioli E.

Genet Med. 2010 Jan;12(1):12-8. doi: 10.1097/GIM.0b013e3181c8e160. Review.

11.

Molecular mechanisms involving prostate cancer racial disparity.

Hatcher D, Daniels G, Osman I, Lee P.

Am J Transl Res. 2009 Apr 20;1(3):235-48.

12.

Genetic variation in CYP17A1 and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California.

Duell EJ, Holly EA, Kelsey KT, Bracci PM.

Int J Cancer. 2010 Feb 1;126(3):790-5. doi: 10.1002/ijc.24792.

13.

Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database.

Bañez LL, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1208-12. doi: 10.1158/1055-9965.EPI-08-0502. Epub 2009 Mar 31.

14.

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.

Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD.

Clin Cancer Res. 2008 Jun 1;14(11):3312-8. doi: 10.1158/1078-0432.CCR-07-4118.

15.

Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.

Sarma AV, Dunn RL, Lange LA, Ray A, Wang Y, Lange EM, Cooney KA.

Prostate. 2008 Feb 15;68(3):296-305. doi: 10.1002/pros.20696.

16.

Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.

Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD.

Urology. 2007 Aug;70(2):217-20. Erratum in: Urology. 2016 Sep;95:225.

Supplemental Content

Support Center